Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target

Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target

Needham analyst Serge Belanger upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Hold to Buy and maintains $14 price target.

February 22, 2023

1 minute read

Needham analyst Serge Belanger upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Hold to Buy and maintains $14 price target.

Comparative Study: Fiserv And Industry Competitors In Financial Services Industry

June 5, 11:00 AM

In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors…

September 28, 9:16 AM

Benchmark analyst Matthew Harrigan maintains Comcast (NASDAQ:CMCSA) with a Buy and lowers the price target from $60 to $46.

March 10, 11:51 AM

Wedbush analyst Robert Driscoll maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and raises the price target from $25 to $20.

November 9, 6:03 AM

Cyngn (NASDAQ: CYN) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.20) by 150 percent.